Kaleido Biosciences Equity 2025

Kaleido Biosciences Aktienanalyse

What does Kaleido Biosciences do?

Kaleido Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of novel therapeutics for a variety of metabolic and immune disorders. The company, based in Lexington, Massachusetts, was founded in 2015 by David Berry, Michael Fischbach, Geoff von Maltzahn, and Noubar Afeyan. The founders brought together their expertise from various fields to develop a new class of drugs based on the manipulation of the microbial ecosystem in the human gut. The company has developed an innovative business model based on the Microbiome Metabolic Therapies (MMT) platform. This platform utilizes naturally occurring, non-pathogenic microorganisms to modulate specific metabolic pathways in the human body. By manipulating the microbiome, scientists at Kaleido Biosciences can influence specific disease states and develop new therapies for metabolic and immune system disorders. One of the areas of focus for the company is the treatment of various metabolic disorders, with a particular emphasis on regulating carbohydrate metabolism. Kaleido Biosciences uses the MMT platform to modify certain bacteria in the gut. The goal is to shift the balance of the gut flora in a way that promotes or suppresses specific metabolic reactions in the body. Another important area of focus is immunotherapy. The aim is to selectively influence the body's immune system to treat various disease states. Kaleido Biosciences is working on strategies to activate bacteria in the gut and trigger specific immune responses. In recent years, the company has developed several promising products and is currently in the clinical trial phase. One product is an MMT candidate for the treatment of celiac disease, an autoimmune disorder related to gluten digestion. Another product is an MMT candidate for the treatment of hyperammonemia in patients with ornithine transcarbamylase deficiency. Kaleido Biosciences also collaborates closely with various companies and partners to further develop its technology platform and identify new products. In 2018, the company entered into a strategic collaboration agreement with Pfizer to identify and develop a range of MMT candidates for the treatment of metabolic and immune disorders. Overall, Kaleido Biosciences Inc has made remarkable progress in a short period of time and developed an innovative technology platform for the development of new therapeutics for complex disease states. The company has quickly established a solid value creation community of investors, partners, and customers. With continued research efforts, partnership endeavors, and a customer-oriented approach, the future looks bright for Kaleido Biosciences. Kaleido Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Kaleido Biosciences's Equity

Kaleido Biosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kaleido Biosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kaleido Biosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kaleido Biosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kaleido Biosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kaleido Biosciences stock

What is the equity of Kaleido Biosciences this year?

Kaleido Biosciences has equity of 0 USD this year.

What was the equity of Kaleido Biosciences compared to the previous year?

The equity of Kaleido Biosciences has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Kaleido Biosciences?

A high equity is advantageous for investors of Kaleido Biosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Kaleido Biosciences?

A low equity can be a risk for investors of Kaleido Biosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Kaleido Biosciences affect the company?

An increase in equity of Kaleido Biosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Kaleido Biosciences affect the company?

A reduction in equity of Kaleido Biosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Kaleido Biosciences?

Some factors that can affect the equity of Kaleido Biosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Kaleido Biosciences so important for investors?

The equity of Kaleido Biosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Kaleido Biosciences take to change the equity?

To change equity, Kaleido Biosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Kaleido Biosciences pay?

Over the past 12 months, Kaleido Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kaleido Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kaleido Biosciences?

The current dividend yield of Kaleido Biosciences is .

When does Kaleido Biosciences pay dividends?

Kaleido Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kaleido Biosciences?

Kaleido Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kaleido Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kaleido Biosciences located?

Kaleido Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kaleido Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kaleido Biosciences from 8/11/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2025.

When did Kaleido Biosciences pay the last dividend?

The last dividend was paid out on 8/11/2025.

What was the dividend of Kaleido Biosciences in the year 2024?

In the year 2024, Kaleido Biosciences distributed 0 USD as dividends.

In which currency does Kaleido Biosciences pay out the dividend?

The dividends of Kaleido Biosciences are distributed in USD.